Monday - June 11, 2018Phosphorus just the tonic for needy cowsStrong demand from vets and farmers // Highest amount of phosphorus available for nutritional supplementation More
Thursday - May 31, 2018Treatment to tackle the country’s two leading causes of blindness now funded on the Pharmaceutical ScheduleEYLEA® (aflibercept) is available under PHARMAC funding from 1 June for the treatment of Wet Age Related Macular Degeneration (wet-AMD) and Diabetic Macular Oedema (DMO) More
Friday - May 25, 2018Bayer is making good progress strategicallyAcquisition of Monsanto expected to be closed in the near future / 2017 sales and earnings at the prior-year level / Dividend to be raised for the eighth time in succession – to 2.80 euros per share / Start to fiscal 2018 overshadowed by currency effects More
Thursday - May 03, 2018Bayer Q1 2018: Operational business held back by currency effects – Major progress with Monsanto acquisitionGroup sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year due to currency effects / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed More
Wednesday - March 21, 2018European Commission conditionally approves Bayer’s proposed acquisition of MonsantoClosing of transaction planned for the second quarter of 2018 More
Wednesday - February 28, 2018Bayer: business at prior-year level – on track with strategyGroup sales increased by 1.5 percent (Fx & portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil – measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated – additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects More
Monday - December 04, 2017Partnership a boost for rural health and wellbeingFocus on rural youth health and suicide prevention // Collaboration key to success // $80,000 initial investment More
Wednesday - November 15, 2017Heiko Schipper to join Bayer Board of Management and head Consumer Health DivisionErica Mann to leave Bayer effective March 31, 2018 More
Thursday - October 26, 2017Bayer Q3 2017: Sales and earnings increasedCovestro deconsolidated / Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million / EBITDA before special items up by 4.1 percent to EUR 2,204 million / Net income of EUR 3,881 million including Covestro book profit More
